Colorectal cancer starts in the colon or rectum, but "metastatic" means it has traveled. That is where the plot gets nastier. A tumor in one place is bad enough. A tumor with luggage is a whole different noir.
The old way to think about stage IV colorectal cancer was: pick a chemotherapy backbone, add something sensible, and hope the cellular miscreants behave. The modern way is more forensic. Before the first major treatment decision, clinicians want the tumor's molecular fingerprints: mismatch repair or MSI status, RAS mutations, BRAF V600E, HER2 amplification, NTRK fusions, and sometimes more.
Why? Because metastatic colorectal cancer is not one villain. It is a lineup.
Some tumors have deficient mismatch repair or high microsatellite instability, meaning their DNA repair system is about as reliable as a screen door in a hurricane. Those tumors pile up mutations, which can make them easier for the immune system to recognize. That is why checkpoint inhibitors can work so well in this subgroup. In KEYNOTE-177, pembrolizumab improved progression-free survival compared with chemotherapy for MSI-H or dMMR metastatic colorectal cancer, helping turn immunotherapy from "interesting witness" into "prime evidence" (DOI: 10.1016/S1470-2045(22)00197-8).
The Tumor's Address Matters
One wonderfully annoying fact about colorectal cancer: location matters. A tumor from the left side of the colon may respond differently than one from the right side, even when the labels look similar. Cancer biology, ever the dramatic suspect, refuses to use one clean filing system.
For patients with RAS wild-type, left-sided metastatic disease, anti-EGFR antibodies such as panitumumab or cetuximab can be especially useful partners with chemotherapy. The PARADIGM trial found longer overall survival with panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 in RAS wild-type, left-sided metastatic colorectal cancer (DOI: 10.1001/jama.2023.4428).
That is the kind of detail guidelines exist to preserve. Without them, treatment can become a restaurant menu where everything sounds plausible and half the entrees are named FOLFOX.
BRAF: The Guy in the Hat
Then there is BRAF V600E, a mutation with bad-guy energy. It shows up in a minority of metastatic colorectal cancers, but when it does, clinicians pay attention. Historically, BRAF-mutated colorectal cancer has behaved aggressively, like it knows a back exit.
The evidence has moved quickly here. Earlier work established encorafenib plus cetuximab as a standard option after prior treatment in BRAF V600E-mutant metastatic colorectal cancer (DOI: 10.1200/JCO.20.02088). More recently, BREAKWATER tested encorafenib and cetuximab with mFOLFOX6 in untreated BRAF V600E-mutant metastatic disease, pushing targeted therapy closer to the first scene of the crime (DOI: 10.1056/NEJMoa2501912).
That is a big shift in attitude. Instead of waiting for the suspect to make three more mistakes, you bring the right handcuffs early.
Not Every Weapon Is a Drug
The guideline also keeps a close eye on local treatments: surgery, ablation, radiation-based approaches, and other ways to attack metastases directly. This matters especially when disease is limited, such as metastases mostly in the liver or lung. In select patients, shrinking disease with systemic therapy can convert "not removable" into "maybe removable," which is oncology's version of finding a hidden door behind the bookcase.
But this is not cowboy medicine. The guideline emphasizes multidisciplinary management because metastatic colorectal cancer often needs medical oncologists, surgeons, radiologists, pathologists, radiation oncologists, and interventional specialists comparing notes. Basically, a heist crew, but legal and with more acronyms.
Later Lines Still Count
When cancer progresses after standard chemotherapy and targeted approaches, the case is not closed. Later-line options have improved. SUNLIGHT showed that adding bevacizumab to trifluridine-tipiracil improved survival in refractory metastatic colorectal cancer (DOI: 10.1056/NEJMoa2214963). FRESCO-2 showed benefit for fruquintinib in heavily pretreated patients (DOI: 10.1016/S0140-6736(23)00772-9).
These are not magic trapdoors out of cancer. They are more like extra pages in the playbook, and for patients running low on options, extra pages matter.
The Real Plot Twist
The most interesting thing about this guideline is not one drug. It is the whole investigative method. Test the tumor. Map the spread. Ask whether local treatment could help. Match therapy to biology. Reassess. Follow the evidence without pretending every patient fits the same template.
Metastatic colorectal cancer remains a hard case. But the detective work is getting sharper. The fingerprints are clearer. The suspect has fewer shadows to hide in.
References
-
Cremolini C, Chalabi M, Elez E, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2026;37(6):759-776. https://doi.org/10.1016/j.annonc.2026.03.005
-
Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for MSI-H or dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis. Lancet Oncology. 2022;23(5):659-670. https://doi.org/10.1016/S1470-2045(22)00197-8
-
Yoshino T, Watanabe J, Shitara K, et al. Panitumumab vs bevacizumab added to first-line chemotherapy in RAS wild-type, left-sided metastatic colorectal cancer. JAMA. 2023;329(15):1271-1282. https://doi.org/10.1001/jama.2023.4428
-
Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine. 2023;388:1657-1667. https://doi.org/10.1056/NEJMoa2214963
-
Elez E, Yoshino T, Shen L, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2501912
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.